6. Concluding remarks
According to the evidence discussed in this review article, the risk of new-onset T2DM in relationship with statin treatment is not negligible, especially for specific subset of patients. However, most authors empha- sized that the benefits of CVD reduction by statin therapy seem to far ex- ceed the risk of T2DM development itself. In any case, statin-driven T2DM appeared to be a medication class-effect, mostly not related to potency nor to individual statin, as well as to be independent of previ- ous history of CVD [25].